AOD-9604 is a modified 16-amino acid fragment corresponding to the fat-burning region (amino acids 176-191) of human growth hormone (hGH). It was specifically engineered to isolate the lipolytic (fat-burning) activity of growth hormone without the growth-promoting or diabetogenic effects.
The peptide stimulates lipolysis (fat breakdown) by mimicking the way natural growth hormone regulates fat metabolism. It activates beta-3 adrenergic receptors on adipocytes (fat cells), triggering the release of stored fatty acids for energy. Crucially, AOD-9604 does not affect blood sugar levels or promote insulin resistance — a key advantage over full-length growth hormone.
AOD-9604 also inhibits lipogenesis — the process by which the body converts non-fat food sources into stored body fat. This dual mechanism (increasing fat breakdown while reducing fat storage) is what makes it attractive for body composition optimization.
Additional research has explored AOD-9604's potential in cartilage regeneration, where it appears to stimulate proteoglycan and collagen synthesis in chondrocytes.
AOD-9604 has been studied in both animal models and human clinical trials, with a particular focus on obesity and metabolic applications.
Fat Loss (Human Trials): In a 12-week double-blind, placebo-controlled trial, obese subjects receiving AOD-9604 showed statistically significant weight loss compared to placebo. The peptide demonstrated a favorable safety profile without effects on IGF-1 levels, glucose tolerance, or insulin sensitivity.
Lipolysis Mechanism: In vitro studies on human and rat adipose tissue confirmed that AOD-9604 stimulates lipolysis at rates comparable to full-length hGH, without the associated glucose or insulin effects.
Cartilage Repair: Australian research demonstrated that AOD-9604 stimulates proteoglycan synthesis in human cartilage explants and may promote cartilage regeneration. This led to clinical trials in osteoarthritis that explored intra-articular injection.
Safety Profile: AOD-9604 received GRAS (Generally Recognized As Safe) status from the FDA for use as a food ingredient, which, while not directly relevant to peptide therapy, supports its favorable safety data.
The following protocols are reported from clinical practice. This is not medical advice. Consult a licensed healthcare provider before starting any peptide therapy.
AOD-9604 is primarily administered via subcutaneous injection. Reported clinical protocols include:
Standard Fat Loss Protocol: 300 mcg per day, injected subcutaneously in the abdominal area, preferably on an empty stomach in the morning. Most providers recommend fasting for 30–60 minutes after injection.
Enhanced Protocol: Some providers use 500 mcg per day for individuals with higher body fat percentages or plateaued weight loss.
Stacking: AOD-9604 is commonly combined with Tesamorelin for enhanced fat loss, or paired with GLP-1 agonists (Semaglutide, Tirzepatide) for patients who want additional metabolic support without the GLP-1 side effects.
Cycle Length: 8–12 weeks on, 4 weeks off. Results are typically enhanced when combined with caloric deficit and exercise.
AOD-9604 is considered one of the safest peptides in the fat loss category, supported by its GRAS designation. Commonly reported effects include mild injection site redness, occasional headache during the first week, and temporary water retention.
Unlike full-length growth hormone, AOD-9604 does not cause hyperglycemia (elevated blood sugar), insulin resistance, carpal tunnel syndrome, or joint swelling. It does not elevate IGF-1 levels, which means it lacks the growth-promoting effects (and associated risks) of hGH therapy.
Verified suppliers with third-party testing and COA documentation. Use code POWER where applicable.
AOD-9604 is a small fragment (amino acids 176-191) of the full growth hormone molecule. It isolates only the fat-burning mechanism without the growth-promoting, blood sugar-elevating, or IGF-1-raising effects of full hGH. This makes it significantly safer for metabolic applications.
Yes, some providers combine AOD-9604 with GLP-1 agonists like Semaglutide or Tirzepatide. AOD-9604 targets fat metabolism through a different pathway (beta-3 adrenergic receptors) than GLP-1s (appetite suppression and insulin signaling), so they can complement each other.
Most providers recommend injecting AOD-9604 on an empty stomach (first thing in the morning) and waiting 30–60 minutes before eating. This is because insulin can interfere with the peptide's lipolytic activity.
Most users report noticing changes in body composition at 4–6 weeks when combined with appropriate diet and exercise. Full protocol results are typically assessed at 8–12 weeks. AOD-9604 is not a rapid weight-loss agent — it supports gradual fat metabolism improvement.
Take our 2-minute quiz to get a personalized peptide recommendation based on your goals, experience level, and health priorities.
Take the Peptide Quiz →This content is for informational and educational purposes only. It is not intended as medical advice and should not be used to diagnose, treat, cure, or prevent any disease or condition. Always consult with a qualified healthcare provider before starting any peptide therapy or supplement regimen. Peptide protocols described on this page reflect reported clinical practices and published research — not recommendations. Individual results may vary. Read full disclaimer.
Affiliate Disclosure: PeptideOnline.co participates in affiliate programs with suppliers featured on this page. We may earn a commission on qualifying purchases at no additional cost to you. Our editorial content is independent and not influenced by affiliate relationships. Learn more.